Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

• 主要な著者: Daniel Morales-Cano (著者), Jose Luis Izquierdo-García (著者), Bianca Barreira (著者), Sergio Esquivel-Ruiz (著者), Maria Callejo (著者), Rachele Pandolfi (著者), Palmira Villa-Valverde (著者), Ignacio Rodríguez (著者), Angel Cogolludo (著者), Jesus Ruiz-Cabello (著者), Francisco Perez-Vizcaino (著者), Laura Moreno (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background: Despite increasing evidence suggesting that pulmonary arterial hypertension (PAH) is a complex disease involving vasoconstriction, thrombosis, inflammation, metabolic dysregulation and vascular proliferation, all the drugs approved for PAH mainly act as vasodilating agents. Since excessi...